Tidal Investments LLC Buys Shares of 16,500 Grifols, S.A. (NASDAQ:GRFS)

Tidal Investments LLC purchased a new position in Grifols, S.A. (NASDAQ:GRFS) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 16,500 shares of the biotechnology company’s stock, valued at approximately $147,000.

Several other large investors also recently made changes to their positions in GRFS. Brandes Investment Partners LP lifted its holdings in Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after purchasing an additional 1,481,924 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in shares of Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after buying an additional 881,155 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of Grifols by 18.7% during the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after buying an additional 1,244,000 shares during the period. Whitebox Advisors LLC grew its stake in Grifols by 56.2% in the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after buying an additional 1,519,093 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in Grifols by 4.7% in the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock worth $13,931,000 after acquiring an additional 100,131 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Stock Performance

GRFS opened at $7.82 on Thursday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The stock’s 50 day moving average price is $8.31 and its two-hundred day moving average price is $8.12. The firm has a market capitalization of $5.38 billion, a P/E ratio of 8.06 and a beta of 0.43. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.